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Abstract
Background: Expressive writing involves writing about stressful or traumatic experiences. Despite trials in people
with advanced disease, no systematic review to date has critiqued the evidence on expressive writing in this
population. To synthesise the evidence of the effects of expressive writing on pain, sleep, depression and anxiety in
people with advanced disease.
Methods: A systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses guidelines. CINAHL, CENTRAL, PsycINFO and PubMed were searched from January 1986 to March 2018.
Other sources included clinical data registers and conference proceedings. Studies were included if they were
randomised controlled trials that assessed the impact of an intervention involving expressive writing for adults with
advanced disease and/or studies involving linguistic analysis on the expressive writing output. Methodological
quality was assessed using the Cochrane risk of bias tool and the Mixed Methods Appraisal Tool. The Grading of
Recommendations Assessment, Development and Evaluation tool was used to assess the level of evidence for the
outcomes of interest. The protocol of this systematic review has been registered on PROSPERO (CRD42017058193).
Results: Six eligible studies with a total of 288 participants were identified, including four randomised controlled
trials. All of the trials were in cancer and recruited predominantly women. None of the interventions were tailored
to the population. Studies had methodological shortcomings and evidence was generally of low quality. Combined
analysis of the four trials, involving 214 participants in total, showed no clear difference in the effect of expressive
writing on sleep, anxiety or depression compared to an active control. Pain was not evaluated in the trials. In
contrast, analysis of the four studies that included linguistic analysis alluded to linguistic mechanisms for potential
effects.
Conclusion: Although the trial results suggest there is no benefit in expressive writing for people with advanced
disease, the current evidence is limited. There is a need for more rigorous trials. It would be of benefit first to
undertake exploratory research in trial design including how best to measure impact and in tailoring of the
intervention to address the specific needs of people with advanced disease.
Trial registration: The protocol of this systematic review has been registered on PROSPERO, which can be
accessed here (registration number: CRD42017058193).
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Introduction
People living with progressive advanced chronic diseases,
such as those at an advanced stage of cancer or renal fail-
ure, experience a decline in physical and psychosocial
functioning and an increasing need for care and support.
They often report sleep problems, low mood and anxiety
[1, 2]. Moreover, people with advanced disease are a clin-
ical population with complex needs and commonly report
intense fear and thoughts about their eventual death and
loss of hope [3]. There are various, often complex, multi-
component, therapeutic approaches available such as
psychosocial interventions [4, 5], supportive-expressive
therapy [6] and legacy leaving interventions [7]. Evidence
suggests that these types of interventions may enhance
well-being and other outcomes in people with advanced
disease [7–9]. These interventions, however, have been
under-evaluated in this population, and some are poten-
tially costly to implement, as they require specialist
personnel providing support over several months. This is
perhaps reflected in varied, scant provision and limited
practice guidelines [10]. Palliative care clinicians also re-
port that they have limited access to referring patients to
psychological services [11]. Moreover, with increasing
pressure on service funding, there is an even greater need
for evidence of intervention benefit [12].
Expressive Writing (EW), is a simple, potentially
inexpensive, therapeutic intervention which involves
writing daily for 15–20 min over 3–4 consecutive
days [13]. EW can be completed at home [14] with-
out the need for facilitation, a specialist therapist or
a dedicated facility. It is an approach that has been
found in primary research to aid the healing process
following a traumatic experience and can bring
about a reduction in biological indicators of stress
and stress-related illness [15, 16]. EW has also been
shown in individual studies to produce positive
health benefits for clinical populations including ef-
fects on blood pressure [17], immune function [18],
wound healing [19], sleep [20], depression [21], and
pain [22]. It has been shown to serve as a significant
means for people to remain socially active and to
seek social support [23]. In people with advanced
disease, the effects of EW are yet to be explored at
review level. However, there are recent systematic re-
views of trials in progressive and long-term condi-
tions, many of which are in cancer patients
(irrespective of disease stage) and survivors. Their
findings on the impact of EW are mixed [24–27].
None of these reviews conclude that this interven-
tion does not work in these populations, providing a
reason to look further at trials in advanced disease.
Instead they highlight that the intervention has not
been sufficiently evaluated in high quality large trials.
The reviews also point to challenges they found
reviewing impact across trials because of heterogen-
eity in intervention and comparison arm protocol,
outcome measurements and population groups. They
raise concerns about the limited consideration given
by trialists to tailoring the intervention to the spe-
cific needs of the population, or subgroups of the
population in question (e.g., stage of disease). This is
particularly relevant given the significant differences
in physical capability (e.g., ability to comfortably
complete a writing session) and psychological pres-
sures (e.g., fears about approaching death) that are
likely to exist between those living with early stage
or chronic illness compared to those with advanced
or terminal disease. They also question the consider-
ation of the size of impact which whilst small may
be clinically relevant in such ill populations. All
recommend further studies of rigorous design to de-
termine whether it is therapeutically effective. One
also highlights the potential underuse of linguistic
analysis in evaluation of impact [24].
There are a number of theories about the processes
that underlie EW [28]. For example, the psychosomatic
theory of inhibition combines the notion of emotion in-
hibition with an element of cognitive processing [15].
This theory suggests that the act of inhibiting thoughts
and feelings surrounding a traumatic experience requires
physiological effort [15]. The physiological energy used
to store and conceal personal trauma can result in ru-
mination about the event and the accumulation of stress
can lead to a higher rate of disease. However, this ac-
count of expressive disclosure relies on recounting and
reappraising relatively inhibited trauma. Research sug-
gests that describing emotions surrounding an imaginary
event or a positive experience can also have health bene-
fits [29–31]. A more plausible explanation is the emo-
tion regulation view of EW, which takes into account
the role of mastery in managing emotions, physiological
responses and behaviours associated with the trauma
[31, 32]. This interpretation suggests that the therapeutic
element of emotional arousal following expressive dis-
closure is the important component, rather than the
stimulus that produced the response. Thereby, disclosure
functions as an affect regulation process, with the act of
confronting thoughts and feelings associated with
trauma improving perceptions of control and self-effi-
cacy over the negative emotions experienced as a result
of adversity.
Using the Linguistic Inquiry and Word Count (LIWC
[33]) tool, the writing of expressive writers can also be
analysed to provide insight into how language use might
be linked with health benefits and the potential mecha-
nisms driving EW [34–36]. The LIWC is a software pro-
gram designed to evaluate whether and how language use
might be linked with improved health. LIWC groups
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words into various categories such as grammar and parts
of speech (e.g., pronouns, verbs, tense) and psychological
(e.g., positive and negative emotions, achievement), social
and cognitive processes (e.g., causation and insight) [37].
It is suggested that through the act of writing, cognitive
changes occur as individuals organise their thoughts and
feelings into a coherent narrative and understand better
their negative experiences [38]. This is evident by the in-
creased use of causal and insight words, indicating that ex-
pressive writers are attempting to find meaning in their
experience [38].
Despite a number of studies, a preliminary scope of
the literature found that to date no systematic review
has evaluated the current evidence on efficacy of EW in
adults with advanced disease. Thus, this review will
examine whether EW could be beneficial for this clinical
population with specific physical and psychological
needs. Taking the results of reviews in broader popula-
tions, we may find clearer results in this more focused
population. Moreover, to enhance critique of the evi-
dence, the review will draw on the authors conclusions
of these broader reviews in exploring, for instance, lin-
guistics and whether there was tailoring of the interven-
tion to the population. The aims of this systematic
review are to:
1) Critique the trial evidence on EW as a therapeutic
intervention for adults with advanced disease.
2) Explore the linguistic analysis of the participants’
EW in order to identify potential processes by
which benefits occur.
Method
The protocol for this review is registered on PROSPERO
(CRD42017058193) and follows the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA [39]) (See Additional file 1: Table S1).
Inclusion criteria
The type of studies selected was based on the two objec-
tives of the systematic review [1]; RCTs and other com-
parative studies such as non-randomised experiments
and before-and-after studies were eligible and [2] studies
which reported the results of linguistic analysis.
Study participants were adults (aged 18 or over) with a
diagnosis of advanced disease such as advanced/metastatic
cancer and/or treated with a palliative care intent. Studies
with children or patients without a diagnosis of advanced
disease and/or patients being treated with a curative care
intent were not included. As it was envisaged that there
may be few studies whose samples completely fulfilled this
criteria it was decided to also include studies whose sam-
ples consisted of > 50% advanced stage disease patients.
Where such studies were identified, we sought to report
findings only on the subgroup with advanced disease. If
this was not possible, we reported findings for the whole
group but take into account the limitations of doing this
in our conclusions.
Studies which used EW as a structured therapeutic
intervention were included. Studies were eligible if they
used emotion provoking EW tasks as a method of reliev-
ing psychological or physical symptoms experienced by
people with advanced disease. Studies with EW tasks
which were not designed to be emotionally arousing or
studies which included EW as part of a group therapy or
as a psychotherapeutic intervention were not eligible. Trial
suitable comparators were writing tasks that were non-
emotionally arousing, no EW task, or treatment as usual.
Case studies, studies with a diary format and qualita-
tive studies were excluded. Studies that assessed the
value of EW for family carers were not included.
Outcomes of interest
Our primary outcomes of interest were pain, sleep, de-
pression and anxiety. They were selected because they
are relevant to a population with advanced disease and
they are commonly measured outcomes for therapeutic
interventions in palliative care (e.g. [8, 9]). Also individ-
ual studies in other populations has found that EW has
a positive impact on these outcomes [20–22, 40].
Search strategy
Electronic bibliographic databases including the Cumula-
tive Index to Nursing and Allied Health Literature
(CINAHL), Cochrane Central Register of Controlled Trials
(CENTRAL), PsycINFO and PubMed were searched from
1986 to March 2018. A variation of Medical Subject
Headings (MeSH) terms and free-text terms on emotional
disclosure and end-of life were applied. The emotional dis-
closure terms were adapted from a similar review [24] and
end-of-life terms recommended by the Cochrane Palliative
Care research group were used. Studies were included if
they were published in English and after 1986 to reflect
studies conducted after the original paradigm was devel-
oped [13]. Table 1 presents an example of the search strat-
egy string used for the PsycINFO database, which was then
adapted and applied to the remaining databases.
The European Union clinical trials register, clinical-
trials.gov, the European Association for Palliative Care
(EAPC) conference abstract proceedings for the last six
years (2012–2017) and reference lists of included studies
and relevant review articles were also checked to identify
additional citations. A research interest list compiled by
the British Psychological Society (BPS) was also used to
contact other researchers who had expressed an interest
in this field to find out if they were aware of any studies
which may be relevant to this review.
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Study selection
The process of selecting relevant studies was con-
ducted by two independent reviewers for all citations
(GC and NK). Firstly, titles and abstracts were
assessed using the inclusion criteria. The full-text re-
view process was completed for studies that met the
inclusion criteria or for studies with unclear rele-
vance. Study authors were contacted if the relevance
of a paper was unclear. Any disagreements in eligi-
bility criteria that arose between the two reviewers
were resolved through discussion and consensus. A
third reviewer (BC) was consulted if discrepancies
were unresolved.
Data extraction
Data were extracted from each study using a standar-
dised form developed by two reviewers (GC and NK).
One reviewer (GC) completed the data extraction
process in full. A second reviewer (NK) checked the ex-
tracted data and disagreements were resolved with the
contribution of a third reviewer (BC). Data extraction in-
cluded study characteristics (author, year, country), aim
of the study, patient characteristics (gender, ethnicity,
patient population, care setting), sample size, tasks
(characteristics of the experimental and control tasks),
and follow-up assessments. Outcome data such as risk
ratios, means and standard deviations were extracted or
generated if appropriate for all outcomes of interest.
Additional information was requested from authors
where necessary.
Quality assessment
Two methodological quality assessment tools were used
to examine the included studies. Comparative studies
were assessed using the Cochrane Collaboration’s risk of
bias tool [41]. The criteria assessed eight domains: selec-
tion bias, (random sequence generation and allocation
concealment), performance bias (blinding of participants
and personnel), detection bias (blinding of outcome as-
sessment), attrition bias (incomplete outcome data) and
sample size. Each domain was rated as either high risk,
low risk or unclear risk of bias.
The Mixed Methods Appraisal Tool (MMAT [42])
was used to assess the quality of the studies which did
not employ an RCT design. Each study was assessed on
study design, selection bias, measurement appropriate-
ness, participant comparability, sampling strategy, repre-
sentativeness of the sample, complete outcome data and
response rate. An overall quality percentage and a de-
scriptive score was calculated for each of the studies ac-
cording to the number of criteria met. The total score
was calculated using the total number of criteria that the
studies met divided by four. Scores ranged from 25 to
100%. Two independent reviewers completed the
Cochrane risk of bias assessment and the MMAT tool.
Reviewers met to compare the quality appraisal ratings
and consensus was reached through discussion.
The evidence for each primary outcome of the in-
cluded RCTs was assessed by the Grading of Recom-
mendations Assessment, Development and Evaluation
(GRADE) system [43]. GRADE does not judge the qual-
ity of the individual studies, but takes into account the
results across the studies and from any combined ana-
lyses [44]. The GRADE approach incorporates criteria
for downgrading the quality of evidence derived from
trials [45]. When the grade of evidence is judged as low,
this indicates that future research might change the esti-
mate of effect. A very low grade of evidence indicates
that it is likely the estimate of effect is markedly different
from the true effect. The quality of evidence is down-
graded in the presence of study limitations (risk of bias),
imprecision (small sample size, width of confidence in-
tervals), indirectness (comprehensive population, inter-
vention, control, and outcomes criteria; population,
intervention, control, and outcomes found across trials
to have extreme differences in direction of results
[PICO]), publication bias and inconsistency (over 80%
statistical heterogeneity in outcomes, interventions).
Data analysis/synthesis
For reported dichotomous data the risk ratios (RRs) and
their confidence intervals (CI) were extracted or generated
if appropriate data were provided in the study. For re-
ported continuous data the mean difference (MD) and the
standard deviation (SD) were extracted or computed if ap-
propriate from the extracted data. If three or more studies
were identified with data for one of our outcomes of inter-
est, a meta-analysis was considered based on sufficient
homogeneity in key characteristics across studies using
the Review Manager 5.3 tool [46]. For any combined ana-
lyses, statistical heterogeneity was calculated with the I2
measure provided by the Review Manager 5.3 tool [46].
Allowing for normal distribution of the studies’ outcomes,
a random-effects model was then used to combine data
across studies found to have substantial statistical hetero-
geneity (> 50%) [47]. Conversely, allowing for power
Table 1 Search strategy string for PsycINFO database
Story writing OR written paradigm OR descriptive writing OR emotional
disclosure OR written emotional disclosure OR emotional expression OR
illness narrative OR self-disclosure OR Pennebaker OR express* OR
expressive writing OR writ* OR writing cure OR creat* OR reflect* OR
catharsis OR trauma OR diary OR therapeutic writing OR therapeutic
disclosure OR diary keeping
AND
((palliat* or terminal* or endstage or hospice* or metastatic or (end adj3
life) or (care adj3 dying) or ((advanced or late or last or end or final) adj3
(stage* or phase*))))
Note. * = truncation symbol in order to find variations and plurals of words
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detection of the studies’ outcomes, a fixed-effects model
was used for studies which had a < 50% statistical hetero-
geneity. For the second objective of the review, findings
from the included studies were explored narratively using
the data on word use and whether use of particular cat-
egories of words (i.e., emotion, cognitive) was associated
with improvements in the outcomes of interest.
Results
Search results and study selection
Figure 1 presents the study selection process. The search
yielded 11,306 unique citations. Following screening, 35
full-text papers were reviewed for potential eligibility
and 29 were excluded. The reasons for exclusion were
interventions that did not use EW (n = 19), studies with
< 50% of participants with advanced disease (n = 5) or a
sample of patients not diagnosed with advanced disease
(n = 4), or patients who were being treated with a
curative intent (n = 1). Six studies met the inclusion cri-
teria. Four of them were RCTs [20, 48–50]. One of the
other studies employed a non-randomised experiment
[51] and the other reported the results of linguistic ana-
lyses of expressive writers’ entries from an RCT [52].
These were included in the linguistic analyses along with
de Moor, Sterner [20] and Mosher, DuHamel [50].
Study characteristics
Two tables summarise the characteristics of the included
studies. Table 2 provides summaries of the four RCTs
[20, 48–50]. Table 3 provides summaries of studies with
linguistic analysis [20, 50–52].
All studies were published between 2002 and 2013.
All but one study (United Kingdom; Imrie and Troop
[51]) was conducted in the USA. Sample sizes ranged
from 6 to 86 participants. In total, across the studies,
there were 288 participants. Participants’ diagnoses
Fig. 1 PRISMA flow diagram of study
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were metastatic/advanced breast cancer [49, 50, 52],
advanced cancer [48] and renal-cell carcinoma [20].
One study had mixed sample participants with ad-
vanced stage disease including secondary cancer and
life-limiting illness [51]. As per gender distributions,
all but one study [20] included predominantly or
exclusively female participants [48–52]. Mean age
ranged from 51 to 58.5 years. Participants were
predominantly white [48–50, 52], while ethnic com-
position was not reported in two studies [20, 51].
The settings where participants completed the writing
tasks included at home [49, 50], at a day hospice [51], in a
laboratory [20] and in hospital palliative care units [48, 52].
The number of intervention sessions, their duration and
their administration intervals varied to some extent across
the studies. All studies consisted of four writing sessions ex-
cept for Imrie and Troop [51] which consisted of two ses-
sions. The duration of the sessions, where this was
reported, was between 20 and 30min. The sessions were
administered over four consecutive days [52], over two
weeks [48, 51], over three weeks [49], over four weeks [20],
and over four to seven weeks [50]. The outcome assess-
ments for studies were performed at baseline and then im-
mediately post-intervention [20, 48], one week post-
intervention [51], eight weeks post-intervention [50], three
months post-intervention [49, 52] and four, six, eight and
ten weeks post-intervention (data averaged across five fol-
low-up assessments [20]).
The majority of studies instructed participants to
write about their deepest emotions, thoughts and feel-
ings specifically surrounding their cancer experience
[20, 49, 50, 52] or about a traumatic and upsetting or
difficult event [48, 51]. Several different neutral
prompts for the control task were used including
writing about daily habits and activities [48, 50],
health-related behaviours [20], and facts about their
cancer diagnosis and treatment [49]. In contrast, one
study used an emotionally-arousing task as a control
condition by instructing participants to write about
an event that took place the previous week which
Table 2 Summary of RCTs examining the effectiveness of an EW task in palliative care/advanced disease samples
Study characteristics Setting, task and assessments Measures and results
Bruera (2008)*
N = 24
Population: Advanced Cancer
Gender: EW: 75% female; Control: 66%
female
Median age: EW: 55.4; Control: 54.3
Ethnicity: EW: 92% White, 8% African
American; Control: 58% White, 25% African
American, 17% Hispanic
Setting: Inpatient and outpatient palliative
care clinic
Task: EW: Trauma (n = 12); Control:
everyday behaviours and habits (n = 12)
Four sessions for 20 min over two weeks
Assessments: Baseline and before and
after each writing session
Measures: STAI assessed anxiety levels before and after each
writing session
Results: STAI median scores (range): EW: Pre-writing State
Anxiety = 34.5 (25–41); Post-intervention State Anxiety = 40
(26–44); Control: Pre-writing State Anxiety = 35 (20–48); Post-
intervention State Anxiety = 37 (20–44)
De Moor (2002)
N = 42
Population: Renal cell carcinoma
Gender: 85.7% male
Mean age: 56.4
Ethnicity: Not reported
Setting: Lab-based
Task: EW: Cancer-related emotions (n =
21); Control: Health behaviours (n = 21)
Four sessions for 20 min over four weeks
Assessments: Immediately post-
intervention and at four, six, eight, and 10
weeks
Measures: PSQI assessed sleep quality; POMS assessed
depression, anxiety and fatigue; IES assessed distress
Results: Follow-up scores showed that the EW group (M =
6.8, SE = 0.6) reported less sleep disturbance at follow-up
compared with the control group (M = 8.7, SE = 0.7) but no
differences were found for depression (EW: M = 7.4, SE = 1.1;
Control: M = 6.6, SE = 1.2), anxiety (EW: M = 6.9, SE = 0.8;
Control: M = 7.0, SE = 0.9), distress (EW: M = 17.4, SE = 1.7;
Control: M = 14.6, SE = 1.8) and fatigue (EW: M = 9.5, SE = 1.0;
Control: M = 9.6, SE = 1.1)
Low (2010)
N = 62
Population: Metastatic breast cancer
Gender: All female
Mean age: 53.8 (SD = 10.8, range = 29–78)
Ethnicity: 87% White
Setting: Home based
Task: EW: Cancer-related emotions (n =
31); Control: Facts about cancer diagnosis
and treatment (n = 31)
Four sessions for 20 min over three weeks
Assessments: Baseline and three months
post-intervention
Measures: PSQI assessed sleep quality; CES–D assessed
depression; IES assessed distress
Results: Follow-up scores showed no differences between
the EW and control groups for sleep (EW: M = 7.1, SE = 0.51;
Control: M = 6.6, SE = 0.51), depression (EW: M = 12.8, SE =
1.47; Control: M = 13.2, SE = 1.48) and distress (EW: M = 8.7,
SE = 0.94; Control: M = 10.1, SE = 0.96)
Mosher (2012)
N = 86
Population: Advanced breast cancer
Gender: All female
Mean age: EW: 57.4 (SD = 12.5); Control:
58.5 (SD = 11.7)
Ethnicity: 81.4% White, 7% African
American, 5.8% Hispanic, 5.8% Other
Setting: Home based
Task: EW: Cancer-related emotions (n =
44); Control: Previous day’s activities (n =
42)
Four sessions for 20 min over four-seven
weeks
Assessments: Eight weeks post-
intervention
Measures: PSQI assessed sleep quality; CES-D assessed
depression; HADS-A assessed anxiety; DT assessed general
distress; FACIT-F assessed fatigue
Results: Follow-up scores showed no differences between
the EW and control groups for sleep (EW: M = 8.42, SE = 0.39;
Control: M = 7.83, SE = 0.39), depression (EW: M = 17.99, SE =
1.35; Control: M = 17.87, SE = 1.38), anxiety (EW: M = 7.15,
SE = 0.48; Control: M = 7.87, SE = 0.49), distress (EW: M = 4.53,
SE = 0.36; Control: M = 4.37, SE = 0.37) and fatigue (EW: M =
30.38, SE = 1.17; Control: M = 32.58, SE = 1.20)
Note. * = study not included in the meta-analysis; CES-D = Center for Epidemiologic Studies-Depression Scale [53]; DT = Distress Thermometer [54]; EW = Expressive
Writing; FACIT-F = Functional Assessment of Chronic Illness Therapy-Fatigue [55]; HADS-A = Hospital Anxiety and Depression Scale [56]; IES = Impact of Events Scale
[57]; M =Mean; POMS = Profile of Mood States [58]; PSQI = Pittsburgh Sleep Quality Index [59]; SS = Standard Error; STAI = State-Trait Anxiety Inventory [60]
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provoked worry [51] but this was to contrast with the
self-compassion prompt used for the EW task.
Risk of bias assessment of RCTs
Online Additional file 2: Table S2 summarises the qual-
ity appraisal of the included RCTs. Overall, the studies
had an unclear risk of bias. Three of the four studies
were found to be low risk for selection bias [20, 49, 50].
The allocation concealment was considered unclear in
most studies except for Low, Stanton [49] which used
sequentially numbered envelopes to conceal the alloca-
tion of tasks for each participant. The majority of the
studies were graded as low risk for attrition except for
Bruera, Willey [48] which reported a high drop-out rate
(75%) and all studies were graded as high risk of bias for
sample size due to small samples employed (< 50 per
trial arm).
Mixed methods appraisal tool (MMAT)
Online Additional file 3: Table S3 presents the quality
appraisal of the two studies with multiple methods de-
signs [51, 52]. The Imrie and Troop [51] study was rated
at 75%, whilst the study by Laccetti [52] scored 50%. Re-
search questions and objectives were clearly defined and
stated in both studies while a common strength was that
the measurements used were appropriate and validated.
Imrie and Troop [51] did not appropriately discuss the
random allocation process. On the other hand, sampling
strategies were sufficiently detailed in the Laccetti [52]
study. Regarding complete outcome data, Imrie and
Table 3 Summary of studies reporting linguistic analyses
Study characteristics Setting, task and assessments Measures and results
De Moor (2002)
Design: RCT
N = 42
Population: Renal cell
carcinoma
Gender: 85.7% male
Mean age: 56.4
Ethnicity: Not reported
Setting: Lab-based
Task: EW: Cancer-related emotions (n = 21); Control: Health
behaviours (n = 21)
Four sessions for 20 min over four weeks
Assessments: Immediately post-intervention and at four,
six, eight, and 10 weeks
Linguistic analyses: conducted using the LIWC
Results: EW and control groups differed in the words they
used for 24 of the 32 categories suggesting emotional
and cognitive processing and expression of their cancer
experience
Imrie & Troop (2012)
Design: Non-randomised
experiment
N = 6
Population: Secondary
cancer or life-limiting illness
Gender: 61.5% female
Mean age: 67.5 (SD = 14.9;
range = 38–86)
Ethnicity: Not reported
Setting: Day Hospice
Task: EW: Difficult experience from the previous week
followed by expressing compassion for the self in the
entry (n = 3); Control: Difficult experience from the previous
week (n = 3)
Three sessions for 20 min over three weeks
Assessments: Baseline and one-week post-intervention
Linguistic analyses: conducted using the LIWC
Results: Both groups reduced the number of negative
words they used between baseline and follow-up (F1,18 =
6.97, p < 0.02) but compared to the control group, the
expressive writers increased the number of causal words
used over time (F1,18 = 8.36, p < 0.01)
Laccetti (2007)
Design: Secondary analysis
of EW entries from RCT
N = 68
Population: Metastatic
breast cancer
Gender: All females
Mean age: 51 (range = 36–
78)
Ethnicity: 94% White, 5%
Native American, 1% Other
Setting: Outpatient clinics
Task: EW: Four sessions for 20–30min over four
consecutive days about experiences, thoughts and feelings
related to not fully recovering from cancer and facing
death, and traumatic and upsetting experiences in life that
may or may not relate to cancer
Assessments: Within one week of study entry and three
months post-intervention
Linguistic analyses: conducted using the LIWC
Measures: FACT-B assessed quality of life
Results: Expressive writers who used more positive
emotion words reported higher scores on emotional well-
being (β = 1.87 [95% CI 0.33, 3.42], p = 0.02) and concerns
related to their breast cancer of FACT-B (β = 1.75 [95% CI
0.17, 3.33] p = 0.03) three months post-intervention
compared to those who used more negative emotion
words
Mosher (2012)
Design: RCT
N = 86
Population: Advanced
breast cancer
Gender: All female
Mean age: EW: 57.4 (SD =
12.5); Control: 58.5 (SD =
11.7)
Ethnicity: 81.4% White, 7%
African American, 5.8%
Hispanic, 5.8% Other
Setting: Home based
Task: EW: Cancer-related emotions (n = 44); Control:
Previous day’s activities (n = 42)
Four sessions for 20 min over four-seven weeks
Assessments: Eight weeks post-intervention
Linguistic analyses: conducted using the LIWC
Results: EW group used a higher proportion of positive
(η2p = 0.13, p < 0.001) and negative (η2p = 0.46, p < 0.001)
words compared to the control group
Note. EW = Expressive Writing; FACT-B = Functional Assessment of Cancer Therapy – Breast [61]; LIWC = Linguistic Inquiry and Word Count
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Troop [51] reported their response rates while Laccetti
[52] failed to report them sufficiently.
Effect of EW on primary and secondary outcomes
Included studies that reported outcomes for sleep, de-
pression, and distress outcomes were suitable for
pooling in combined analyses. A variety of self-report
measures were used to assess outcomes including the
Pittsburgh Sleep Quality Index (PSQI [59]) for sleep,
Center for Epidemiologic Studies – Depression scale
(CES-D [53]) for depression, the Distress Thermom-
eter (DT [54]) for distress and the Profile of Mood
States (POMS [58]) for anxiety and fatigue. The fre-
quency and duration of EW was similar across the
studies despite variations in the time period in which
the tasks were completed. All studies reported
continuous data. Online Additional file 4: presents
the results of the pooled outcomes for sleep, depres-
sion and distress.
Primary outcomes of interest: results and judgement of
quality of results
Pain
Although two studies examined the effects of EW on
pain, one study did not report the data on pain due to
high attrition [48] and one study reported the effects of
EW on a number of somatic symptoms including pain
but did not report the effects on pain separately [49].
Sleep
Data from three studies measuring sleep were pooled with
a total sample of 183 participants [20, 49, 50]. In the com-
bined analysis from all time points (mean scores averaged
across immediately post-intervention and four, six, eight
and ten weeks post-intervention [20]; 3months [49]; 8
weeks [50]) there was no statistically significant effect of
EW on sleep between the trials arms with a standardised
mean difference (SMD) of − 0.12 [95% CI − 1.51, 1.26]. The
data showed high heterogeneity across the trials (I2 = 65%,
p = 0.06). (See online Additional file 4: Figure S1).
Depression
As in the combined analysis at follow-up, three studies
of 183 participants [20, 49, 50] demonstrated no statisti-
cally significant effect of EW on depression between the
trials arms (SMD = 0.02 [95% CI -0.27, 0.31]). There was
no evidence of heterogeneity among the trials (I2 = 0%,
p = 0.88). (See online Additional file 4: Figure S2).
Anxiety
Two studies with a total of 121 participants both showed
that the intervention had no statistically significant effect
on anxiety (MD = -0.10 [− 2.46, 2.26] [20]; MD = -0.72
[95% CI -2.06, 0.62] [50]).
Secondary outcomes of interest
Distress
As in combined analysis at follow-up, data from three
studies with a total of 183 participants [20, 49, 50]
showed no statistically significant improvements of EW
on distress between the trial arms (SMD = -0.03 [95% CI
-0.32, 0.26]). There was no evidence of statistical hetero-
geneity across the trials (I2 = 0%, p = 0.52). (See online
Additional file 4: Figure S3).
Fatigue
Two studies with a total of 121 participants both
showed that the intervention had no statistically sig-
nificant effect on fatigue (MD = -0.10 [95% CI -3.01,
2.81] [20]; MD = -2.20 [95% CI -5.49, 1.09] [50]).
Grade
Overall, the quality of evidence for the primary outcomes
was rated as low. For the primary outcomes of sleep, anx-
iety and depression the grade of evidence was downgraded
due to some important factors. First, data from three stud-
ies [20, 49, 50] measuring sleep had inconsistencies as they
were presented in combined analysis with substantial statis-
tical heterogeneity (I2 = 65%). For the primary outcome of
depression, data from the same three studies showed im-
precision as they had small sample sizes and limitations to
study quality due to unclear risk of bias. Finally, the evi-
dence for the effectiveness of EW on anxiety from two
studies was also rated as low as these studies showed im-
precisions due to small sample sizes and unclear risk of bias
due to underreporting [20, 50].
Linguistic analysis
Four studies used the LIWC [33] to analyse word use
across EW text entries [20, 50–52]. While de Moor, Sterner
[20] found that the use of cognitive words increased in the
EW group, Imrie and Troop [51] found this was especially
true in the use of causal words in those who were writing
about stress with an additional self-compassionate compo-
nent. There were also changes in the use of emotion words
across text entries in the EW groups although the results
here were more mixed. Mosher, DuHamel [50] found that
the EW group used more positive and negative emotion
words while Imrie and Troop [51] found a reduction in
negative emotion words in both the control and EW
groups. Laccetti [52] found that greater use of positive emo-
tion words was related to improvement in quality of life.
The EW task in the Mosher, DuHamel [50] study prompted
the intervention group to express themselves using emo-
tional words and thus the authors found that, compared
with the control group, expressive writers used a higher
percentage of both positive and negative emotion words.
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Discussion
This systematic review sought to critique evidence
evaluating EW in advanced disease. All of the stud-
ies identified involved adults with advanced disease
and from these, five, including the four RCTs, in-
volved adults with advanced cancer. The results
showed, on current evidence, that EW does not have
a beneficial effect in people with advanced cancer in
terms of primary outcomes of sleep, depression or
anxiety or secondary outcomes of distress and fa-
tigue. However, the evidence is based on only a few
studies which have significant methodological limita-
tions as judged using GRADE [43]. Notably, al-
though two of the trials assessed the effects of EW
on pain, they did not report the outcome of this as-
sessment. Which is important considering that previ-
ous research with breast cancer survivors who
completed an EW task reported a reduction in pain
at the three-month post-intervention follow-up [21].
Notwithstanding the lack of evidence, these findings
are consistent with studies which found no effect of EW
on sleep [62] or anxiety [40]. The evidence for the effect
of EW on depression is equivocal, as positive effects
have been reported at three months but not at nine-
month follow-up in breast cancer survivors [21]. On the
other hand, perhaps in an advanced disease population
it might be overly optimistic to expect an improvement
in these outcomes, given the patients are extremely un-
well and likely to have deteriorating health. We selected
these outcomes based on knowledge elsewhere of their
relevance. However this choice did not deviate from
those used in the trials of populations with advanced
disease. Few other outcomes such as quality of life or
qualitative patient-reported opinion were measured in
these trials. Perhaps future research should consider the
types of outcomes that could be impacted by the inter-
vention in this population.
The studies identified in this review used two to four
sessions of EW over two to seven weeks which may not
have been sufficient to produce beneficial effects. Thus a
tailored EW intervention with an adequate but suitable
and feasible number of sessions for people with advanced
cancer is required. Moreover, the format of EW may not
be appropriate for all patients in this population, where
some may find the act of writing regularly too much to
commit too and other easier formats such as recorded
spoken expression may be more appropriate.
The synthesis of the linguistic analyses revealed that
participants who completed the EW task used an in-
creasing number of emotional words including both
positive and negative emotion words [50] but it is the
use of positive emotion words that is related to greater
emotional well-being [52]. Moreover, expressive writers
were found to use more cognitive words relating to
causal understanding in their text entries suggesting cog-
nitive changes [51].
Strengths and weaknesses
The present review was conducted in accordance with
the PRISMA criteria [39]. A comprehensive search for
relevant studies was conducted using four electronic da-
tabases, clinical data registers, published conference ab-
stract proceedings, reference lists of included studies,
review articles and a research interest list compiled by
the British Psychological Society (BPS) for additional ci-
tations. Authors of included studies were contacted for
study clarifications and missing information and to en-
quire of any literature which may have been missed by
the search process. In order to maximise the number of
eligible studies, it was decided to include all studies
which employed samples consisting of > 50% patients
with advance disease. In fact, in all studies reviewed, all
participants had advanced disease and results may there-
fore be representative of this population. The present re-
view assessed the quality of studies and evidence using
the Cochrane risk of bias assessment [41] and the
GRADE [43] system, respectively. Finally, an important
strength of the present review is the use of meta-analysis
which provides a pooled estimate of EW effects. All
available data were pooled after ensuring that the follow-
ups and the outcome measures were similar enough to
allow combined analyses.
This review has some potential limitations. Among the
most important ones is that the sample sizes of the in-
cluded studies were small, ranging from 6 to 86 partici-
pants. This indicates caution should be taken in
interpreting the results as small studies may account for
false-positive results [63]. Furthermore, some may argue
that there was insufficient data to combine, however the
combined analysis is not misleading as studies were suf-
ficiently homogeneous and by using the GRADE system
to judge quality of evidence, we highlight that we base
our conclusions on limited evidence. The assessment
follow-ups also varied between the studies from immedi-
ately post-intervention to three months with one study
averaging the follow-up scores across assessments com-
pleted immediately post-intervention and at four, six,
eight and ten weeks post-intervention [20]. Also, one
study conducted basic statistical analyses comparing me-
dian scores by “eye-balling” the data [48]. After contact-
ing the authors, they confirmed that this was due to
insufficient power and high attrition. Therefore, further
conclusions cannot be drawn from this study. Addition-
ally, studies did not recruit people with other life-limit-
ing conditions except for cancer and, as such, findings
cannot be generalised to other advanced conditions.
Moreover, there was a significant limitation with regards
to the overall methodological quality of the included
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studies, which was considered to be unclear according
to the Cochrane risk of bias tool, with the evidence also
considered to be of low quality according to the GRADE
approach.
Implications for practice and research
EW is a low cost, relatively simple and easy intervention
to administer. Where it has been shown to have signifi-
cant beneficial effects, it is appealing to propose adding
EW as a standalone intervention or an adjunct to exist-
ing services. The findings of this review suggest the evi-
dence for the benefits of EW in people with advanced
disease is simply not there at present. This though may
relate to trial design and quality of execution. Moreover,
since the pattern of word use is consistent with those
studies that do show benefits [64] and that participants
report EW as personal, meaningful and valuable [51], we
argue that it is worth pursuing this line of research with
better quality studies before reaching a final conclusion.
Specifically, studies need to be sufficiently powered, to
have enough writing sessions, and to have a long enough
follow-up. Tailoring the methodology of emotional dis-
closure interventions to address the specific needs of
people with advanced disease (e.g., in terms of frequency
and location of sessions, precise disclosure instructions,
type of practical and emotional support available and
whether disclosure should be spoken or written) may im-
prove its acceptability and potential usefulness with this
population. Similarly, further exploration of outcome meas-
urement focusing on what impact EW may have in this
very ill population could help identify any potential benefit.
A collaborative project funded by the Economic and Social
Research Council and Marie Curie awarded to our team
will be exploring these gaps in our understanding.
Moreover, even if a positive effect for EW (or other
form of emotional disclosure intervention) can be identi-
fied, further research should investigate the way in which
these interventions can be used to supplement existing
therapies in palliative care settings with the aim to im-
prove the overall well-being of people with advanced dis-
ease. Trial evidence to date, where the effect of
psychological therapies have been reviewed in this set-
ting, has been found to be unclear on impact [9] or lim-
ited in quality [8]. If emotional disclosure is to be
included as a therapeutic intervention, either as a stan-
dalone intervention or as part of a multi-component
treatment, then it is advisable that harmful effects of ex-
pressing emotions should also be assessed.
Notably, studies included in this review have recruited
predominantly female participants. Whilst it was not pos-
sible to investigate gender as a potential moderator in this
review, it would be useful for future research to explore
whether males and females with advanced disease respond
differently to emotional disclosure interventions. Reviews
to date have found contradictory findings with Smyth [62]
reporting that men experience more benefits than women
whilst the findings of Reinhold, Bürkner [65] suggest that
females benefit more from EW.
There may also be other outcomes that are important to
measure and measures of outcomes that are sufficiently
sensitive to detect small changes. As discussed above, pain
was not adequately reported as a standalone outcome.
However, there is some suggestion that EW was related to
an increase in visits to mental health services [50] which
has also been found in other EW studies such as for people
following their first myocardial infarction [66]. Moreover,
EW was more beneficial for those who reported low levels
of social support at baseline [49] which is in line with find-
ings that posit that EW benefits people with fewer oppor-
tunities for emotional support [67] and can even improve
perceived levels of support in women with cancer [68].
These additional outcomes, if appropriately measured, may
be important to consider. RCTs provide a quantitative
measure of outcomes which may not assess what patients
value or how they would like an EW intervention to be de-
livered. Therefore, quantitative data should be supple-
mented with qualitative data [69].
It is also worth focusing on the association between
the use of positive words and improvements in well-
being. It is recommended that more studies need to
evaluate this association and to expand our under-
standing of the duration of the effects of emotional
disclosure. Additionally, given the fact that the LIWC
is unable to identify traces of irony or sarcasm, it per-
haps needs to be considered how these paramount ele-
ments of language could be incorporated into the
LIWC [33] or alternatively through coding of voice re-
cordings by independent raters.
Conclusion
The findings of this review highlight that the use of EW
as a therapeutic intervention in people with advanced
disease is feasible but that a more tailored, focused inter-
vention may be required in order to improve outcomes.
These then should be tested in high quality adequately
powered studies.
Additional files
Additional file 1: Table S1: PRISMA 2009 Checklist. (DOCX 27 kb)
Additional file 2: Table S2: Risk of bias assessment across RCTS. (DOCX
32 kb)
Additional file 3: Table s3: Results of MMAT quality appraisal. (DOCX 14 kb)
Additional file 4: Results of the meta-analysis for the outcomes of interest.
Figure S1. Pooled data comparing the effectiveness of EW on sleep (sleep
quality/sleep duration) compared with the control task. Figure S2. Pooled
data comparing the effectiveness of EW on depression compared with the
control task. Figure S3. Pooled data comparing the effectiveness of EW on
distress compared with the control task. (DOCX 31 kb)
Kupeli et al. BMC Palliative Care           (2019) 18:65 Page 10 of 12
Abbreviations
EW: Expressive Writing; GRADE: Grading of Recommendations Assessment,
Development and Evaluation; LIWC: Linguistic Inquiry and Word Count;
MMAT: Mixed Methods Appraisal Tool; RCT: Randomised Control Trial
Acknowledgements
The authors would like to thank Profs Eduardo Bruera, Carl De Moor, Janet
De Moor, Laura Porter, Alyssa Averill, Gail Ironson, Cindy Carmack and
Lorenzo Cohen for responding to requests for additional information on
their studies.
Authors’ contributions
NK and BC conceived the research and managed all elements of the work.
NK, GC, NT, DM, PS and BC contributed to the design of the study. NK, BC
and GC developed the search terms. GC and NK completed the database
searches and reviewed all titles, abstracts and full text studies. GC extracted
data from all studies, and synthesised the data with BC. BC oversaw the
quality appraisal and data synthesis. GC, NK and BC drafted the manuscript
and NT, DM and PS provided critical review on the manuscript. All authors
read and approved the final manuscript.
Funding
Nuriye Kupeli is supported by Alzheimer’s Society Junior Fellowship grant
funding (Grant Award number: 399 AS-JF-17b-016). Paddy Stone and Bridget
Candy are supported by a Marie Curie core grant (MCCC-FCO-16-U). Daisy
McInnerney is supported by a Marie Curie and Economic and Social Research
Council collaborative grant (MCCC-ESR-17-U). The funding bodies of this
research had no role in the design of the study; collection, analysis, and
interpretation of data; and in writing the manuscript.
Availability of data and materials
The datasets used and/or analysed during the current review are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
NK and BC are associate editors for BMC Palliative Care but they had no
involvement in the editorial handling of this paper. GC, NT, DM and PS
declare no conflict of interest with respect to the research, authorship, and/
or publication of this article.
Author details
1Marie Curie Palliative Care Research Department, Division of Psychiatry,
University College London, 6th Floor, Maple House, 149 Tottenham Court
Road, London W1T 7NF, UK. 2Department of Psychology, City University of
London, London, UK. 3Department of Psychology and Sport Sciences,
University of Hertfordshire, Hertfordshire, UK.
Received: 14 December 2018 Accepted: 25 July 2019
References
1. Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence
of depression, anxiety, and adjustment disorder in oncological, haematological,
and palliative-care settings: a meta-analysis of 94 interview-based studies. The
Lancet Oncology. 2011;12(2):160–74.
2. Potter J, Hami F, Bryan T, Quigley C. Symptoms in 400 patients referred to
palliative care services: prevalence and patterns. Palliat Med. 2003;17(4):310–4.
3. Ellis LM, Blanke CD, Roach N. Losing “losing the Battle with Cancer”. JAMA
Oncol. 2015;1(1):13.
4. Badr H. Psychosocial interventions for patients with advanced cancer and
their families. Am J Lifestyle Med. 2016;10(1):53–63.
5. von Heymann-Horan AB, Puggaard LB, Nissen KG, Benthien KS, Bidstrup P,
Coyne J, et al. Dyadic psychological intervention for patients with cancer
and caregivers in home-based specialized palliative care: the Domus model.
Palliat Support Care. 2017;16(2):189–97.
6. Spiegel D, Spira J. Supportive-expressive group therapy: a treatment manual
of psychosocial intervention for women with recurrent breast cancer:
psychosocial treatment laboratory; 1991.
7. Keall RM, Clayton JM, Butow PN. Therapeutic life review in palliative
care: a systematic review of quantitative evaluations. J Pain Symptom
Manag. 2015;49(4):747–61.
8. Okuyama T, Akechi T, Mackenzie L, Furukawa TA. Psychotherapy for
depression among advanced, incurable cancer patients: a systematic review
and meta-analysis. Cancer Treat Rev. 2017;56:16–27.
9. Beatty L, Kemp E, Butow P, Girgis A, Schofield P, Turner J, et al. A systematic
review of psychotherapeutic interventions for women with metastatic
breast cancer: context matters. Psycho-oncology. 2018;27(1):34–42.
10. National Institute for Health and Clinical Excellence. End of life care for
adults: Holistic support - families and carers 2017. Available from: https://
www.nice.org.uk/guidance/qs13/chapter/Quality-statement-7-Holistic-
support-families-and-carers. Accessed 28 Mar 2018.
11. Atkin N, Vickerstaff V, Candy B. ‘Worried to death’: the assessment and
management of anxiety in patients with advanced life-limiting disease, a national
survey of palliative medicine physicians. BMC Palliative Care. 2017;16(1):69.
12. Gardiner C, Ryan T, Gott M. What is the cost of palliative care in the UK? A
systematic review. BMJ Support Palliat Care. 2018. https://doi.org/10.1136/
bmjspcare-2018-001519.
13. Pennebaker JW, Beall SK. Confronting a traumatic event: toward an
understanding of inhibition and disease. J Abnorm Psychol. 1986;95(3):274–81.
14. van Middendorp H, Sorbi MJ, van Doornen LJP, Bijlsma JWJ, Geenen R. Feasibility
and induced cognitive-emotional change of an emotional disclosure intervention
adapted for home application. Patient Educ Couns. 2007;66(2):177–87.
15. Pennebaker JW. Traumatic experience and psychosomatic disease: exploring
the roles of behavioural inhibition, obsession, and confiding. Canadian
Psychology/Psychologie canadienne. 1985;26(2):82–95.
16. Pennebaker JW. Writing about emotional experiences as a therapeutic
process. Psychol Sci. 1997;8(3):162–6.
17. McGuire KMB, Greenberg MA, Gevirtz R. Autonomic effects of expressive
writing in individuals with elevated blood pressure. J Health Psychol. 2005;
10(2):197–209.
18. Petrie KJ, Fontanilla I, Thomas MG, Booth RJ, Pennebaker JW. Effect of
written emotional expression on immune function in patients with human
immunodeficiency virus infection: a randomized trial. Psychosom Med.
2004;66(2):272–5.
19. Weinman J, Ebrecht M, Scott S, Walburn J, Dyson M. Enhanced wound healing
after emotional disclosure intervention. Br J Health Psychol. 2008;13(1):95–102.
20. de Moor C, Sterner J, Hall M, Warneke C, Gilani Z, Amato R, et al. A pilot
study of the effects of expressive writing on psychological and behavioral
adjustment in patients enrolled in a phase II trial of vaccine therapy for
metastatic renal cell carcinoma. Health Psychol. 2002;21(6):615–9.
21. Henry EA, Schlegel RJ, Talley AE, Molix LA, Bettencourt BA. The feasibility
and effectiveness of expressive writing for rural and urban breast Cancer
survivors. Oncol Nurs Forum. 2010;37(6):749–57.
22. Rosenberg HJ, Rosenberg SD, Ernstoff MS, Wolford GL, Amdur RJ, Elshamy
MR, et al. Expressive disclosure and health outcomes in a prostate cancer
population. Int J Psychiatry Med. 2002;32(1):37–53.
23. Pennebaker JW, Graybeal A. Patterns of natural language use: disclosure,
personality, and social integration. Curr Dir Psychol Sci. 2001;10(3):90–3.
24. Merz EL, Fox RS, Malcarne VL. Expressive writing interventions in cancer
patients: a systematic review. Health Psychol Rev. 2014;8(3):339–61.
25. Zachariae R, O'Toole MS. The effect of expressive writing intervention on
psychological and physical health outcomes in cancer patients-a systematic
review and meta-analysis. Psycho-Oncology. 2015;24(11):1349–59.
26. Nyssen OP, Taylor SJ, Wong G, Steed E, Bourke L, Lord J, et al. Does therapeutic
writing help people with long-term conditions? Systematic review, realist
synthesis and economic considerations. Health Technol Assess. 2016;20(27).
27. Zhou C, Wu Y, An S, Li X. Effect of expressive writing intervention on health
outcomes in breast cancer patients: a systematic review and meta-analysis
of randomized controlled trials. PLoS One. 2015;10(7):e0131802.
28. Sloan DM, Marx BP. Taking pen to hand: evaluating theories underlying the
written disclosure paradigm. Clin Psychol Sci Pract. 2004;11(2):121–37.
29. Burton CM, King LA. The health benefits of writing about positive experiences:
the role of broadened cognition. Psychol Health. 2009;24(8):867–79.
30. Low CA, Stanton AL, Danoff-Burg S. Expressive disclosure and benefit
finding among breast cancer patients: mechanisms for positive health
effects. Health Psychol. 2006;25(2):181–9.
Kupeli et al. BMC Palliative Care           (2019) 18:65 Page 11 of 12
31. Greenberg MA, Wortman CB, Stone AA. Emotional expression and physical
health: revising traumatic memories or fostering self-regulation? J Pers Soc
Psychol. 1996;71(3):588.
32. Lepore SJ, Greenberg MA, Bruno M, Smyth JM. Expressive writing and
health: self-regulation of emotion-related experience, physiology, and
behavior. In: Lepore SJ, Smyth JM, editors. The writing cure: how
expressive writing promotes health and emotional well-being.
Washington, DC: American Psychological Association; 2002. p. 99–117.
33. Pennebaker JW, Boyd RL, Jordan K, Blackburn K. The development and
psychometric properties of LIWC2015; 2015.
34. Chung C, Pennebaker JW. The psychological functions of function words.
Social Communication. 2007:343–59.
35. Pennebaker JW, Mayne TJ, Francis ME. Linguistic predictors of adaptive
bereavement. J Pers Soc Psychol. 1997;72(4):863–71.
36. Pennebaker JW, Mehl MR, Niederhoffer KG. Psychological aspects of
natural language use: our words. Our Selves Annual Review of
Psychology. 2003;54(1):547–77.
37. Pennebaker JW, Francis ME, Booth RJ. Linguistic inquiry and word count:
LIWC 2001. Mahway: Lawrence Erlbaum Associates; 2001. p. 71.
38. Francis ME, Pennebaker JW. Linguistic inquiry and word count. Technical
Report. Dallas: Southern Methodist University; 1993.
39. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting
items for systematic reviews and meta-analyses: the PRISMA statement.
PLoS Med. 2009;6(7):e1000097.
40. Niles AN, Haltom KEB, Mulvenna CM, Lieberman MD, Stanton AL.
Randomized controlled trial of expressive writing for psychological and
physical health: the moderating role of emotional expressivity. Anxiety
Stress Coping. 2014;27(1):1–17.
41. Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al.
The Cochrane Collaboration's tool for assessing risk of bias in randomised
trials. BMJ. 2011;343:d5928.
42. Pluye P, Robert E, Cargo M, Bartlett G, O’cathain A, Griffiths F, et al. Proposal:
a mixed methods appraisal tool for systematic mixed studies reviews.
Montréal: McGill University; 2011. p. 1–8.
43. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Akl E, et al.
Chapter 11: Completing ‘Summary of findings’ tables and grading the
confidence in or quality of the evidence. In: JPT H, Churchill R, Chandler J,
Cumpston MS, editors. Cochrane Handbook for Systematic Reviews of
Interventions version 520: Cochrane; 2017.
44. Kavanagh BP. The GRADE system for rating clinical guidelines. PLoS Med.
2009;6(9):e1000094.
45. Dijkers M. Introducing GRADE: a systematic approach to rating
evidence in systematic reviews and to guideline development. KT
Update. 2013;1(5):1–9.
46. Review Manager (RevMan). [Computer program]. Version 5.3. Copenhagen:
The Nordic Cochrane Centre. In: The Nordic Cochrane Centre TCC; 2014.
47. Deeks JJ, Higgins JP, Altman DG. Analysing data and undertaking meta‐
analyses. Cochrane handbook for systematic reviews of interventions
version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011.
48. Bruera E, Willey J, Cohen M, Palmer JL. Expressive writing in patients
receiving palliative care: a feasibility study. J Palliat Med. 2008;11(1):15–9.
49. Low CA, Stanton AL, Bower JE, Gyllenhammer L. A randomized controlled
trial of emotionally expressive writing for women with metastatic breast
cancer. Health Psychol. 2010;29(4):460–6.
50. Mosher CE, DuHamel KN, Lam J, Dickler M, Li Y, Massie MJ, et al.
Randomised trial of expressive writing for distressed metastatic breast
cancer patients. Psychol Health. 2012;27(1):88–100.
51. Imrie S, Troop NA. A pilot study on the effects and feasibility of
compassion-focused expressive writing in day hospice patients. Palliative
and Supportive Care. 2012;10(02):115–22.
52. Laccetti M. Expressive writing in women with advanced breast Cancer.
Oncol Nurs Forum. 2007;34(5):1019–24.
53. Radloff LS. The CES-D scale: a self-report depression scale for research in the
general population. Appl Psychol Meas. 1977;1(3):385–401.
54. Roth AJ, Kornblith AB, Batel-Copel L, Peabody E, Scher HI, Holland JC. Rapid
screening for psychologic distress in men with prostate carcinoma. Cancer.
1998;82(10):1904–8.
55. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring
fatigue and other anemia-related symptoms with the functional
assessment of Cancer therapy (FACT) measurement system. J Pain
Symptom Manag. 1997;13(2):63–74.
56. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta
Psychiatr Scand. 1983;67.
57. Horowitz M, Wilner N, Alvarez W. Impact of event scale: a measure of
subjective stress. Psychosom Med. 1979;41(3):209–18.
58. McNair D, Lorr M, Droppleman L. Profile of mood states: EdITS manual. San
Diego: Educational and Industrial Testing Service; 1981.
59. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh
sleep quality index: a new instrument for psychiatric practice and research.
Psychiatry Res. 1989;28(2):193–213.
60. Spielberger C. Assessment of anger: the state-trait anger expression scale.
Advances in Personality Assessment. 1983;3:112–34.
61. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and
validity of the functional assessment of Cancer therapy-breast quality-of-life
instrument. J Clin Oncol. 1997;15(3):974–86.
62. Smyth JM. Written emotional expression: effect sizes, outcome types, and
moderating variables. J Consult Clin Psychol. 1998;66(1):174–84.
63. Forstmeier W, Wagenmakers E-J, Parker TH. Detecting and avoiding likely
false-positive findings - a practical guide. Biol Rev. 2016;92(4):1941–68.
64. Tausczik YR, Pennebaker JW. The psychological meaning of words: LIWC and
computerized text analysis methods. J Lang Soc Psychol. 2010;29(1):24–54.
65. Reinhold M, Bürkner PC, Holling H. Effects of expressive writing on depressive
symptoms—a meta-analysis. Clin Psychol Sci Pract. 2018;25:e12224.
66. Willmott L, Harris P, Gellaitry G, Cooper V, Horne R. The effects of expressive
writing following first myocardial infarction: a randomized controlled trial.
Health Psychol. 2011;30(5):642.
67. Zakowski SG, Ramati A, Morton C, Johnson P, Flanigan R. Written emotional
disclosure buffers the effects of social constraints on distress among cancer
patients. Health Psychol. 2004;23(6):555.
68. Gellaitry G, Peters K, Bloomfield D, Horne R. Narrowing the gap: the effects
of an expressive writing intervention on perceptions
ofactualandidealemotional support in women who have completed
treatment for early stage breast cancer. Psycho-Oncology. 2010;19(1):77–84.
69. Flemming K. The knowledge base for evidence-based nursing: a role for
mixed methods research? Adv Nurs Sci. 2007;30(1):41–51.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Kupeli et al. BMC Palliative Care           (2019) 18:65 Page 12 of 12
